Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Koschmieder, Steffen
Ruxo-BEAT, NCT02577926: The Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	Active, not recruiting	2	207	Europe	Ruxolitinib, Study drug, Jakavi, BAT, Control Treatment	RWTH Aachen University, Novartis Pharmaceuticals	Polycythemia Vera (PV), Essential Thrombocythemia (ET)	12/27	12/28